144 related articles for article (PubMed ID: 9830619)
1. Biochemical and clinical pharmacology of 5-fluorouracil.
Schilsky RL
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):13-8. PubMed ID: 9830619
[TBL] [Abstract][Full Text] [Related]
2. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
Diasio RB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):23-7. PubMed ID: 9830621
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
Diasio RB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):21-6; discussion 27. PubMed ID: 11219973
[TBL] [Abstract][Full Text] [Related]
4. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio RB
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
[TBL] [Abstract][Full Text] [Related]
6. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
7. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in oral fluoropyrimidine therapies. Proceedings of a meeting. Chicago, Illinois, USA. July 11, 1998.
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):9-56. PubMed ID: 9830618
[No Abstract] [Full Text] [Related]
9. The oral fluorinated pyrimidines.
de Bono JS; Twelves CJ
Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
[TBL] [Abstract][Full Text] [Related]
10. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Mercier C; Ciccolini J
Clin Colorectal Cancer; 2006 Nov; 6(4):288-96. PubMed ID: 17241513
[TBL] [Abstract][Full Text] [Related]
11. Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Haaz MC; Fischel JL; Formento P; Renée N; Etienne MC; Milano G
Cancer Chemother Pharmacol; 1996; 38(1):52-8. PubMed ID: 8603452
[TBL] [Abstract][Full Text] [Related]
12. Dihydropyrimidine dehydrogenase and resistance to 5-fluorouracil.
Diasio RB
Prog Exp Tumor Res; 1999; 36():115-23. PubMed ID: 10386069
[No Abstract] [Full Text] [Related]
13. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Hoff PM; Pazdur R
Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.
Diasio RB; Johnson MR
Clin Cancer Res; 1999 Oct; 5(10):2672-3. PubMed ID: 10537327
[No Abstract] [Full Text] [Related]
16. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
van Kuilenburg AB; Maring JG
Pharmacogenomics; 2013 May; 14(7):799-811. PubMed ID: 23651027
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of 5-fluorouracil.
Macdonald JS
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):33-4. PubMed ID: 10442356
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of eniluracil: current status.
Hohneker JA
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):52-6. PubMed ID: 9830627
[TBL] [Abstract][Full Text] [Related]
20. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Benson AB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
